Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions.

ABSTRACT:

Background

Biologic and targeted synthetic disease modifying agents (b/tsDMARDs) have broadened the treatment landscape for autoimmune diseases particularly in patients refractory to conventional DMARDs. More recently, the introduction of biosimilars has reduced the price of bDMARDs, potentially improving accessibility. Though efficacy and safety have been described, patient attitudes to b/tsDMARDs are not well-understood. We aim to investigate patients' beliefs about biologic and biosimilar therapy, and the factors influencing their perceptions.

Methods

Patient consumer groups (Arthritis Australia, Crohn's and Colitis Australia) assisted in advertising an online questionnaire for people with a self-reported diagnosis of inflammatory arthritis (IA) or inflammatory bowel dise

SUBMITTER: Khoo T 

PROVIDER: S-EPMC9783393 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature